Necrotising enterocolitis (NEC) is a disease that causes inflammation and infection of the bowel in newborn infants, especially those who are premature or low birth weight. NEC most commonly affects immature intestinal tissue and can occur in babies with other medical issues, like lung problems or congenital heart disease. The signs and symptoms of NEC include abdominal swelling and tenderness, vomiting, bloody stools, rapid breathing, temperature instability and lethargy. Early detection and prompt treatment are critical to improve outcomes in newborns with NEC. Treatment for NEC depends on how severe the condition is and may involve antibiotics, fluids, oxygen therapy, surgery to remove damaged portions of the bowel, and in severe cases, a temporary ostomy.
The Necrotising Enterocolitis Market is estimated to be valued at US$ 7.10 Bn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period of 2024-2031.
The increasing incidence of preterm births as a result of rising maternal age and lifestyle factors has significantly contributed to the high prevalence of NEC. Moreover, improved survival of very low birthweight infants owing to advancements in neonatal care has also augmented the risk of NEC.
Key Takeaways
Key players operating in the necrotising enterocolitis market are AbbVie, AstraZeneca, Baxter International, Bristol-Myers Squibb, and Fresenius Kabi.
Some of the key opportunities in the market include development of parenteral nutrition formulas tailored for preterm infants, introduction of probiotics for preventing NEC and development of economical therapies for resource-constrained regions.
Geographically, North America dominates the global necrotising enterocolitis market. However, trends indicate strong growth potential in Asia Pacific and Latin America over the forecast period supported by improving access to healthcare facilities in emerging countries.
Market Drivers
Increasing number of preterm births across the globe is a major factor driving the growth of necrotising enterocolitis market. According to the WHO, prematurity is the leading cause of death among children under 5 years of age, accounting for approximately 1 million deaths in 2015. Additionally, advanced NEC therapies and changing lifestyle factors leading to rise in maternal age and incidence of infertility treatments have also augmented the risk of premature birth and subsequent NEC.
Market Restraints
High cost of treatments especially surgery and TPN limits access to care in low and middle-income countries. Furthermore, lack of definite treatments and poor understanding of disease etiology poses significant challenges to market growth. Late diagnoses also reduce treatment effectiveness and outcomes in newborns with NEC.
Segment Analysis
The Necrotising Enterocolitis Marketis segmented into diagnosis, treatment and end use. The diagnosis segment currently dominates the market due to rising number of premature births and increasing cases of necrotising enterocolitis. Early diagnosis plays a crucial role in improving outcomes of NEC. Going forward, growing awareness for early diagnosis and monitoring of high-risk infants will contribute to the growth of this segment during the forecast period.
The treatment segment is further divided into medications and surgery. The medications segment is expected to hold leading share throughout the forecast period driven by increasing use of antibiotics, blood pressure enhancing drugs, feeding intolerance medications and other drugs to manage NEC cases. The surgery segment is projected to grow at a higher rate owing to rising severity of NEC cases that requires surgical intervention.
Global Analysis
The North America region holds majority share in the Necrotising Enterocolitis Marketstimulated by rising incidence of preterm birth related NEC cases. Increasing healthcare spending and growing awareness about NEC are also supporting the market growth. Asia Pacific region is forecast to emerge as the fastest growing market led by improving healthcare infrastructure and expanding patient pool. Growing premature birth rate across developing nations like India and China offers lucrative opportunities for market players in the region.
Get more insights on this topic: https://www.dailyprbulletin.com/necrotising-enterocolitis-market-trends-by-increasing-preterm-births/
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
What Are The Key Data Covered In This Necrotising Enterocolitis Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Necrotising Enterocolitis Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the Necrotising Enterocolitis Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Necrotising Enterocolitis Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Necrotising Enterocolitis Market vendors
FAQ’s
Q.1 What are the main factors influencing the Necrotising Enterocolitis Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Necrotising Enterocolitis Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Necrotising Enterocolitis Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it